Charbonnier J F, Reboul P, Rougier M, Aubin B, Chassaing J L, Philippe P, Planche R, Hoepfner Petersen H E
Centre Hospitalier Universitaire, Clermont-Ferrand.
Encephale. 1987 Jul-Aug;13(4):249-54.
In an open, clinical trial comprising a total of 49 depressed in-patients, a new selective 5-HT uptake inhibitor citalopram was administered by intravenous infusion in doses of 20-60 mg once daily for per 3 weeks. The therapeutic effect was assessed globally and by means of the CPRS subscale for depression (MADRS). About 40 per cent of the patients showed a complete response whereas about 25 per cent showed a partial response. Side effects which were rated globally and recorded according to a check-list were generally mild and infrequent. The side-effects most frequently observed were tremor, drowsiness, and dizziness which occurred in about 15 per cent of the patients.' Three patients were withdrawn prematurely because of nausea and one because of a skin rash. Cardiovascular recordings were normal except for one patient, who developed a hypertension which may have been related to the test drug. No pathological laboratory values were detected during the trial period. The authors conclude that intravenously administered citalopram is well suited for the treatment of depressed patients.
在一项共有49名住院抑郁症患者参与的开放性临床试验中，一种新型选择性5-羟色胺再摄取抑制剂西酞普兰通过静脉输注给药，剂量为每日20 - 60毫克，每3周一次。通过综合评估以及使用抑郁症状自评量表（MADRS）来评定治疗效果。约40%的患者显示出完全缓解，约25%的患者显示出部分缓解。依据检查表进行综合评定并记录的副作用总体上较为轻微且不常见。最常观察到的副作用是震颤、嗜睡和头晕，约15%的患者出现这些症状。三名患者因恶心提前退出试验，一名患者因皮疹退出。除一名患者出现可能与受试药物有关的高血压外，心血管记录均正常。试验期间未检测到病理性实验室值。作者得出结论，静脉注射西酞普兰非常适合治疗抑郁症患者。
